| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Departments of Orthopedics, Biochemistry, and Molecular Biology, Mayo Graduate School of Medicine, Rochester, Minnesota 55905
Address all correspondence and requests for reprints to: Russell T. Turner, Ph.D., Orthopedic Research, Room 3–69 Medical Science Building, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Trans-3,4,5-trihydroxystilbene (resveratrol), a polyphenolic compound found in juice and wine from dark-skinned grape cultivars, was recently shown to bind to estrogen receptors in vitro, where it activated transcription of estrogen-responsive reporter genes. The purpose of this 6-day study in weanling rats was to determine the dose response (1, 4, 10, 40, and 100 µg/day) effects of orally administered resveratrol on estrogen target tissues. The solvent (10% ethanol) had no significant effect on any measurement or derived value. 17ß-Estradiol treatment (100 µg/day) decreased the growth rate, final body weight, serum cholesterol, and radial bone growth (periosteal bone formation and mineral apposition rates) at the tibia-fibula synostosis. In the uterus, 17ß-estradiol treatment increased wet weight, epithelial cell height, and steady state messenger RNA levels for insulin-like growth factor I. In contrast, resveratrol treatment had no significant effect on body weight, serum cholesterol, radial bone growth, epithelial cell height, or messenger RNA levels for insulin-like growth factor I. Resveratrol treatment resulted in slight increases in uterine wet weight, but significance was achieved at the 10-µg dose only. A second experiment was performed to determine whether a high dose of resveratrol (1000 µg/day) antagonizes the ability of estrogen to lower serum cholesterol. As was shown for the lower doses, resveratrol had no effect on body weight, uterine wet weight, uterine epithelial cell height, cortical bone histomorphometry, or serum cholesterol. 17ß-Estradiol significantly lowered serum cholesterol, and this response was antagonized by cotreatment with resveratrol. These in vivo results suggest, in contrast to prior in vitro studies, that resveratrol has little or no estrogen agonism on reproductive and nonreproductive estrogen target tissues and may be an estrogen antagonist.
This article has been cited by other articles:
 |
|
 |
|
  M. Bottner, J. Christoffel, H. Jarry, and W. Wuttke Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on pituitary function in rats. J. Endocrinol., April 1, 2006; 189(1): 77 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Das and N. Maulik Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., February 1, 2006; 6(1): 36 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Juan, E. Gonzalez-Pons, T. Munuera, J. Ballester, J. E. Rodriguez-Gil, and J. M. Planas trans-Resveratrol, a Natural Antioxidant from Grapes, Increases Sperm Output in Healthy Rats J. Nutr., April 1, 2005; 135(4): 757 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Crowell, P. J. Korytko, R. L. Morrissey, T. D. Booth, and B. S. Levine Resveratrol-Associated Renal Toxicity Toxicol. Sci., December 1, 2004; 82(2): 614 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. PERVAIZ Resveratrol: from grapevines to mammalian biology FASEB J, November 1, 2003; 17(14): 1975 - 1985. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Sibonga, S. Lotinun, G. L. Evans, V. S. Pribluda, S. J. Green, and R. T. Turner Dose-Response Effects of 2-Methoxyestradiol on Estrogen Target Tissues in the Ovariectomized Rat Endocrinology, March 1, 2003; 144(3): 785 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Marier, P. Vachon, A. Gritsas, J. Zhang, J.-P. Moreau, and M. P. Ducharme Metabolism and Disposition of Resveratrol in Rats: Extent of Absorption, Glucuronidation, and Enterohepatic Recirculation Evidenced by a Linked-Rat Model J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 369 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Juan, M. P. Vinardell, and J. M. Planas The Daily Oral Administration of High Doses of trans-Resveratrol to Rats for 28 Days Is Not Harmful J. Nutr., February 1, 2002; 132(2): 257 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. L. Bhat, D. Lantvit, K. Christov, R. G. Mehta, R. C. Moon, and J. M. Pezzuto Estrogenic and Antiestrogenic Properties of Resveratrol in Mammary Tumor Models Cancer Res., October 1, 2001; 61(20): 7456 - 7463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gusman, H. Malonne, and G. Atassi A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol Carcinogenesis, August 1, 2001; 22(8): 1111 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ahmad, V. M. Adhami, F. Afaq, D. K. Feyes, and H. Mukhtar Resveratrol Causes WAF-1/p21-mediated G1-phase Arrest of Cell Cycle and Induction of Apoptosis in Human Epidermoid Carcinoma A431 Cells Clin. Cancer Res., May 1, 2001; 7(5): 1466 - 1473. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Bowers, V. V. Tyulmenkov, S. C. Jernigan, and C. M. Klinge Resveratrol Acts as a Mixed Agonist/Antagonist for Estrogen Receptors {alpha} and {beta} Endocrinology, October 1, 2000; 141(10): 3657 - 3667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-F. Li, S.-A. Chen, and S.-N. Wu Evidence for the stimulatory effect of resveratrol on Ca2+-activated K+ current in vascular endothelial cells Cardiovasc Res, March 1, 2000; 45(4): 1035 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Slater, J Odum, and J Ashby Resveratrol and red wine consumption Human and Experimental Toxicology, October 1, 1999; 18(10): 625 - 626. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
